Dying in the year after surviving: a perspective on elevated all-cause mortality among opioid overdose survivors
It has been reported that opioid overdose survivors who had a prior non-fatal opioid overdose have a substantially elevated one-year all-cause mortality compared to first-time overdose survivors. The objective of this Perspective was to construct a framework for assessing the observed elevated post-overdose one-year mortality burden. We reviewed published peer-reviewed literature in the English language identified through PubMed-MEDLINE, with supplemental searches of JAMA Network, the New England Journal of Medicine (NEJM), and federal surveillance data (e.g. CDC and SAMHSA). References were selected for relevance, prioritizing 2020-2026, and were used as direction to additional sources of material. It was found that elevated one-year mortality among prior overdose survivors reflects at least six interacting mechanistic realms: (1) cumulative hypoxic-ischemic organ injury, including hippocampal atrophy and leukoencephalopathy; (2) cardiopulmonary toxicity and opioid withdrawal-induced cardiomyopathy; (3) opioid-induced immunosuppression with heightened vulnerability to infective endocarditis and sepsis; (4) neuropsychological sequelae including executive dysfunction, amnestic syndrome, and suicidality; (5) opioid tolerance compounded by fentanyl-specific pharmacotoxicology; and (6) sociostructural determinants such as housing instability, racial disparities, and treatment gap with some high-risk populations, including Medicare disability beneficiaries, showing that fewer than 5% received medication for opioid use disorder (MOUD) after nonfatal overdose. Therefore, we propose that elevated postoverdose one-year mortality is not simply a marker of substance-use severity, but also a multi-organ, multi-system consequence of repeated physiological insult, neuropsychological injury, and socioeconomic circumstance.
Authors
- Eugene Vortsman
- Lynn Webster
- Robert B. Raffa (ORCID: https://orcid.org/0000-0002-1456-4451)
- Albert Dahan
- Joseph V. Pergolizzi
Institutions
- Long Island Jewish Medical Center (US)
- Center For Policy Research (US)
- Xilio Therapeutics (United States) (US)
- Nema Research (United States) (US)
- 21c Consultancy (United Kingdom) (GB)
- Temple University (US)
Publication Details
- Journal
- The American Journal of Drug and Alcohol Abuse
- Published
- 2026-09-18
- DOI
- https://doi.org/10.1080/00952990.2026.2714510
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00